<?xml version="1.0" encoding="UTF-8"?>
<p>In a case study on five grimly sick patients having symptoms of severe pneumonia due to COVID-19, convalescent plasma administration was found to be helpful in patients recovering successfully. The convalescent plasma containing a SARS-CoV-2-specific ELISA (serum) antibody titer higher than 1:1,000 and neutralizing antibody titer more significant than 40 was collected from the recovered patients and used for plasma transfusion twice in a volume of 200 to 250â€‰ml on the day of collection (
 <xref rid="B310" ref-type="bibr">310</xref>). At present, treatment for sepsis and ARDS mainly involves antimicrobial therapy, source control, and supportive care. Hence, the use of therapeutic plasma exchange can be considered an option in managing such severe conditions. Further randomized trials can be designed to investigate its efficacy (
 <xref rid="B311" ref-type="bibr">311</xref>).
</p>
